{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:33:25Z","timestamp":1793806405058,"version":"4.6.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,6,29]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Anti-sclerostin treatment increases bone mass and fracture resistance in MM Anti-sclerostin in combination with zoledronic acid is superior to zoledronic acid alone in increasing fracture resistance.<\/jats:p>","DOI":"10.1182\/blood-2017-03-773341","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T01:05:23Z","timestamp":1495069523000},"page":"3452-3464","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":179,"title":["Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma"],"prefix":"10.1182","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-2506","authenticated-orcid":false,"given":"Michelle M.","family":"McDonald","sequence":"first","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2884-6481","authenticated-orcid":false,"given":"Michaela R.","family":"Reagan","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"},{"name":"Maine Medical Center Research Institute, Scarborough, ME;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-2945","authenticated-orcid":false,"given":"Scott E.","family":"Youlten","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhu T.","family":"Mohanty","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Seckinger","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsKlinikum Heidelberg, Medizinische Klinik V, Labors f\u00fcr Myelomforschung, Ruprecht-Karls-Universit\u00e4t Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L.","family":"Terry","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Pettitt","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija K.","family":"Simic","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-7242","authenticated-orcid":false,"given":"Tegan L.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Centre for Children\u2019s Bone and Musculoskeletal Health, The Children\u2019s Hospital at Westmead, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-7699","authenticated-orcid":false,"given":"Alyson","family":"Morse","sequence":"additional","affiliation":[{"name":"Centre for Children\u2019s Bone and Musculoskeletal Health, The Children\u2019s Hospital at Westmead, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence M. T.","family":"Le","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1354-8820","authenticated-orcid":false,"given":"David","family":"Abi-Hanna","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kramer","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne","family":"Falank","sequence":"additional","affiliation":[{"name":"Maine Medical Center Research Institute, Scarborough, ME;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Fairfield","sequence":"additional","affiliation":[{"name":"Maine Medical Center Research Institute, Scarborough, ME;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Baldock","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Little","sequence":"additional","affiliation":[{"name":"Centre for Children\u2019s Bone and Musculoskeletal Health, The Children\u2019s Hospital at Westmead, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Kneissel","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Hematology and Immunology, Frei University, Brussels, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. Duncan","family":"Bassett","sequence":"additional","affiliation":[{"name":"Department of Medicine, Molecular Endocrinology Laboratory, Imperial College, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Molecular Endocrinology Laboratory, Imperial College, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatunde O.","family":"Oyajobi","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsKlinikum Heidelberg, Medizinische Klinik V, Labors f\u00fcr Myelomforschung, Ruprecht-Karls-Universit\u00e4t Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-2984","authenticated-orcid":false,"given":"Tri G.","family":"Phan","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research, Sydney, NSW, Australia;"},{"name":"St. Vincent\u2019s School of Medicine, University of New South Wales, Sydney, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111905232319200_B1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-540-85772-3_2","article-title":"Epidemiology of multiple myeloma","volume":"183","author":"Becker","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"9983","key":"2019111905232319200_B2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"2019111905232319200_B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"2019111905232319200_B4","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111905232319200_B5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019111905232319200_B6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1148\/radiology.204.1.9205246","article-title":"Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging","volume":"204","author":"Lecouvet","year":"1997","journal-title":"Radiology"},{"issue":"13","key":"2019111905232319200_B7","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111905232319200_B8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J Cell Biochem"},{"issue":"13","key":"2019111905232319200_B9","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111905232319200_B10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111905232319200_B11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111905232319200_B12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"3 Suppl","key":"2019111905232319200_B13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.11125","article-title":"Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease","volume":"97","author":"Croucher","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"2019111905232319200_B14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(11)70157-7","article-title":"Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial","volume":"12","author":"Morgan","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111905232319200_B15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"issue":"16","key":"2019111905232319200_B16","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","article-title":"Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment","volume":"67","author":"Giuliani","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"2019111905232319200_B17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"issue":"26","key":"2019111905232319200_B18","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111905232319200_B19","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/ijc.22033","article-title":"Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation","volume":"119","author":"Politou","year":"2006","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111905232319200_B20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019111905232319200_B21","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111905232319200_B22","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111905232319200_B23","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2019111905232319200_B24","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"2019111905232319200_B25","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111905232319200_B26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111905232319200_B27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"issue":"13","key":"2019111905232319200_B28","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"6","key":"2019111905232319200_B29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"issue":"12","key":"2019111905232319200_B30","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","article-title":"Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody","volume":"155","author":"Li","year":"2014","journal-title":"Endocrinology"},{"key":"2019111905232319200_B31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bone.2016.10.019","article-title":"Effects of sclerostin antibodies in animal models of osteoporosis","volume":"96","author":"Ominsky","year":"2016","journal-title":"Bone"},{"key":"2019111905232319200_B32","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat Commun"},{"issue":"10","key":"2019111905232319200_B33","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jor.22109","article-title":"Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats","volume":"30","author":"McDonald","year":"2012","journal-title":"J Orthop Res"},{"key":"2019111905232319200_B34","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jbmr.3038","article-title":"Sclerostin antibody administration converts bone lining cells into active osteoblasts","volume":"32","author":"Kim","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019111905232319200_B35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019111905232319200_B36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111905232319200_B37","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","article-title":"Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma","volume":"113","author":"Hose","year":"2009","journal-title":"Blood"},{"issue":"44","key":"2019111905232319200_B38","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/onc.2009.257","article-title":"Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis","volume":"28","author":"Seckinger","year":"2009","journal-title":"Oncogene"},{"issue":"34","key":"2019111905232319200_B39","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111905232319200_B40","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-07-0121","article-title":"Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging","volume":"6","author":"Oyajobi","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"28","key":"2019111905232319200_B41","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111905232319200_B42","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br J Cancer"},{"issue":"25","key":"2019111905232319200_B43","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2009-07-235960","article-title":"An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization","volume":"114","author":"Jourdan","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111905232319200_B44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2144\/0000113876","article-title":"Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice","volume":"52","author":"Stern","year":"2012","journal-title":"Biotechniques"},{"issue":"1","key":"2019111905232319200_B45","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"2019111905232319200_B46","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nmeth.2483","article-title":"Comparative analysis of RNA sequencing methods for degraded or low-input samples","volume":"10","author":"Adiconis","year":"2013","journal-title":"Nat Methods"},{"key":"2019111905232319200_B47","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"2019111905232319200_B48","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1359\/jbmr.1998.13.9.1451","article-title":"Variation in the short-term changes in bone cell activity in three regions of the distal femur immediately following ovariectomy","volume":"13","author":"Baldock","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019111905232319200_B49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019111905232319200_B50","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111905232319200_B51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/MCB.00992-14","article-title":"WNT signaling: an emerging mediator of cancer cell metabolism?","volume":"35","author":"Sherwood","year":"2015","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2019111905232319200_B52","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"16","key":"2019111905232319200_B53","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111905232319200_B54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/10428194.2013.820288","article-title":"Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease","volume":"55","author":"Kristensen","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"2019111905232319200_B55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2019111905232319200_B56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2014.02.010","article-title":"Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics","volume":"38","author":"Wang","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"2019111905232319200_B57","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"issue":"6","key":"2019111905232319200_B58","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J Bone Miner Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/26\/3452\/1401388\/blood773341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/26\/3452\/1401388\/blood773341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T05:43:23Z","timestamp":1719207803000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/26\/3452\/36245\/Inhibiting-the-osteocytespecific-protein"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":58,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,6,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-03-773341","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]}}}